Accessibility Menu
Protalix BioTherapeutics logo

Protalix BioTherapeutics(NYSEMKT) PLX

Market Cap$190.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-99%
5 Year+60%
1 Year+58%
1 Month+2%
$2.38
+2.37%
+0.06Today
After hours$2.37-$0.01 (-0.42%)
Protalix BioTherapeutics last closing stock price
MetricPriceDate
Last closeUSD 2.372026-08-04
Protalix BioTherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.72%USD 2.332026-07-28
1 month+2.16%USD 2.322026-07-02
3 month+17.33%USD 2.022026-05-06
Year to date+31.67%USD 1.802025-12-31
1 year+58%USD 1.502025-08-04
3 year+42.77%USD 1.662023-08-04
5 year+60.14%USD 1.482021-08-05
Since inception-99.13%USD 271.502007-01-03

Protalix BioTherapeutics Financials at a Glance

Market Cap

$190.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$76.38M

Net Income (TTM)

$15.33M

EPS (TTM)

$0.18

P/E Ratio

12.93

Dividend

$0.00

Beta (Volatility)

0.69 (Low)

Price

$2.38

Volume

716,163.878

Open

$2.33

Previous Close

$2.37

Daily Range

$2.32 - $2.39

52-Week Range

$1.42 - $3.19

Estimated Earnings Date

Aug 13, 2026

PLX News

Foolcom-Featured.png

Protalix Revenue Jumps 16 Percent in Q2

Motley Fool Markets TeamAug 14, 2025
GettyImages-679546546

Why Protalix BioTherapeutics Stock Is Plunging Today

Prosper Junior BakinyApr 28, 2021

The Simplest Biotech Growth Portfolio Ever

Maxx ChatskoNov 18, 2013

Is This Orphan Drugmaker in Trouble?

Leo SunNov 11, 2013
PLX_oralDrink

Can Protalix Revolutionize This Orphan Disease?

Maxx ChatskoOct 15, 2013
procellex-platofrm_advantages_comparison

Should You Buy Protalix for Its Platform Alone?

Maxx ChatskoSep 22, 2013

How Far Can $69 Million Take Protalix?

Maxx ChatskoSep 18, 2013

5 of Last Week's Biggest Losers

Rick MunarrizSep 15, 2013
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Protalix BioTherapeutics

Protalix develops medicines for people with rare genetic diseases. Its products help patients manage conditions like Gaucher and Fabry disease. The company’s therapies are used by hospitals and clinics worldwide.

What’s in the Protalix Toolbox?

  • Enzyme Replacement Therapies (ERTs): Medicines for rare genetic disorders, making up 100% of product sales.
  • Elelyso: Treats Gaucher disease; 56.6% of product sales in 2025; used in over 40 countries.
  • Elfabrio: Treats Fabry disease; 43.4% of product sales in 2025; approved in the US, EU, and more.
  • Pipeline Candidates: Includes PRX-115 (gout), PRX-119 (inflammatory diseases), and PRX-110 (cystic fibrosis), all in various trial stages.
  • Research Collaborations: Works with partners to develop new therapies for rare kidney diseases.

Growth and Expansion: The Protalix Playbook

  • Partnered with Pfizer (2012) for global Elelyso sales, excluding Brazil.
  • Teamed with Fiocruz (2013) for Elelyso in Brazil’s public health system.
  • Formed alliance with Chiesi (2017) for Elfabrio commercialization worldwide.
  • Expanded manufacturing in Israel (2025) to support new product launches.
  • Entered new global markets for Elfabrio after US and EU approvals (2023-2026).

What Makes Protalix Stand Out?

Protalix uses plant cells to make complex medicines, reducing contamination risks. Its business model relies on global partnerships for distribution. The company focuses on rare diseases, targeting markets with few treatment options.

Five Things You Need to Know

  • Revenue was $52.7 million in 2025, down 1.2% from 2024.
  • Product sales: Elelyso 56.6%, Elfabrio 43.4% of 2025 revenue.
  • Operating loss was $5.5 million in 2025, down from $3.9 million income in 2024.
  • Cash and deposits totaled $30.3 million at year-end 2025.

Bottom Line

Protalix has evolved through partnerships and a focus on rare diseases. Its plant-based technology and global reach support ongoing adaptation in a competitive market.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

226

CEO

Dror Bashan, MBA

Website

www.protalix.com

Headquarters

Hackensack, NJ 07601, US

PLX Financials

Key Financial Metrics (TTM)

Gross Margin

69.97%

Operating Margin

25.91%

Net Income Margin

20.07%

Return on Equity

28.10%

Return on Capital

-9.73%

Return on Assets

14.98%

Earnings Yield

7.73%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$190.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

80.57M

Volume

716.16K

Avg. Volume

732.37K

Financials (TTM)

Gross Profit

$53.44M

Operating Income

$19.79M

EBITDA

$22.33M

Operating Cash Flow

$15.09M

Capital Expenditure

-$2.09M

Free Cash Flow

$13.00M

Cash & ST Invst.

$51.79M

Total Debt

$8.48M

Protalix BioTherapeutics Performance Analysis

Protalix BioTherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 47,638,00024.2%
20232023-12-31USD 65,494,00037.5%
20242024-12-31USD 53,399,000-18.5%
20252025-12-31USD 52,744,000-1.2%
Protalix BioTherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3054.8%
Q32025-09-3014.0%
Q42025-12-31-48.9%
Q12026-03-31270.0%
Protalix BioTherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.31-50.7%
20232023-12-31USD 0.09N/A
20242024-12-31USD 0.04-57.8%
20252025-12-31USD -0.08N/A
Protalix BioTherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30104.2%
Q32025-09-301400.0%
Q42025-12-31-329.7%
Q12026-03-31419.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$33.75M

+233.7%

Gross Profit

$29.62M

+1432.5%

Gross Margin

87.77%

N/A

Market Cap

$190.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$844.93K

N/A

Employees

226

N/A

Net Income

$18.32M

+606.1%

EBITDA

$21.74M

+743.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$51.79M

+49.1%

Total Debt

$8.48M

+62.0%

Accounts Receivable

$2.94M

-37.1%

Inventory

$30.47M

+56.2%

Long Term Debt

$7.05M

+84.9%

Short Term Debt

$1.43M

+0.6%

Return on Assets

14.98%

N/A

Return on Invested Capital

26.41%

N/A

Free Cash Flow

$21.26M

+496.4%

Operating Cash Flow

$22.03M

+535.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MDWDMediWound Ltd.
$14.30+0.56%
CHRSCoherus Oncology, Inc.
$1.48+2.78%
IVVDInvivyd, Inc.
$0.57+3.92%
TARAProtara Therapeutics, Inc.
$4.01+1.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$162.66+0.29%
SPCXSpace Exploration Technologies
$125.33+0.09%
NVDANvidia
$211.94+0.03%
INTCIntel
$100.86+0.11%

Questions About PLX

What is the current price of Protalix BioTherapeutics?

Protalix BioTherapeutics is trading at $2.37 per share.

What is the 52-week range for Protalix BioTherapeutics?

Over the past 52 weeks, Protalix BioTherapeutics has traded between $1.42 and $3.19.

How much debt does Protalix BioTherapeutics have?

As of the most recent reporting period, Protalix BioTherapeutics reported total debt of $8.48M.

How much cash does Protalix BioTherapeutics have on hand?

Protalix BioTherapeutics reported $41.71M in cash and cash equivalents in its most recent financial results.

What is Protalix BioTherapeutics’s dividend yield?

Protalix BioTherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services